RxDoctor Payments Data

Jeffrey Roylance, MD

Family Medicine · West Plains, MONPI 1487651931

Payments from drug & device makers

$3,927in general payments, 2019–2025

Across 239 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$702
  • AstraZeneca$516
  • Lilly USA, LLC$485
  • Amgen$341
  • Abbott$226
  • Pfizer$216
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,912100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,927 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$16,428
Medicare patients
262
Services billed
944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$38,345
TrulicityDulaglutide13$20,987
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,167
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,016
Sucralfate15$2,675
Ziprasidone Hcl35$2,561
Potassium Chloride130$2,464
Fentanyl17$2,269
Levothyroxine Sodium222$2,180
Atorvastatin Calcium277$2,038
Metoprolol Succinate93$1,798
Celecoxib40$1,552
Modafinil11$1,211
Gabapentin73$1,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$38,34573 claims
Lilly USA, LLCTrulicity$485$20,98713 claims
AstraZenecaBreztri Aerosphere$516$14,73321 claims
GSKTrelegy Ellipta$15$10,16716 claims
AbbVieSynthroid$38$86217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in West Plains

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →